Search research articles
Contact Us
Filters
Showing results (131-140 of 213) with videos related to
Page
of 22
Sort By:
Circulation
|
September 13, 2019
Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF
Senthil Selvaraj, Brian Claggett, Andrea Pozzi, et al.
JACC. Heart Failure
|
October 15, 2018
Caregivers of Patients Considering a Destination Therapy Left Ventricular Assist Device and a Shared Decision-Making Intervention: The DECIDE-LVAD Trial
Colleen K McIlvennan, Daniel D Matlock, Jocelyn S Thompson, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making
|
May 20, 2020
Decision Aid Implementation among Left Ventricular Assist Device Programs Participating in the DECIDE-LVAD Stepped-Wedge Trial
Daniel D Matlock, Colleen K McIlvennan, Jocelyn S Thompson, et al.
JACC. Heart Failure
|
March 5, 2018
Sudden Death in Heart Failure With Preserved Ejection Fraction: A Competing Risks Analysis From the TOPCAT Trial
Muthiah Vaduganathan, Brian L Claggett, Neal A Chatterjee, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
May 4, 2015
Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
David M Charytan, Eldrin F Lewis, Akshay S Desai, et al.
American Heart Journal
|
October 11, 2011
Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)
John J V McMurray, Hajime Uno, Petr Jarolim, et al.
JACC. Heart Failure
|
October 10, 2024
Race in Heart Failure: A Pooled Participant-Level Analysis of the Global PARADIGM-HF and PARAGON-HF Trials
Henri Lu, Brian L Claggett, Milton Packer, et al.
European Journal of Heart Failure
|
December 18, 2024
Mortality after high-risk myocardial infarction over the last 20 years: Insights from the VALIANT and PARADISE-MI trials
Alberto Foà, Maria A Pabon, Eugene Braunwald, et al.
European Journal of Heart Failure
|
December 26, 2006
Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM
Eldrin F Lewis, Gervasio A Lamas, Eileen O'Meara, et al.
European Journal of Heart Failure
|
July 26, 2024
Acute changes in kidney function and outcomes following an acute myocardial infarction: Insights from PARADISE-MI
Finnian R Mc Causland, Martina M McGrath, Brian L Claggett, et al.
Page
of 22
Search research articles
Search
Showing results (131-140 of 213) with videos related to
Sort By:
Page
of 22
Circulation
|
September 13, 2019
Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF
Senthil Selvaraj, Brian Claggett, Andrea Pozzi, et al.
JACC. Heart Failure
|
October 15, 2018
Caregivers of Patients Considering a Destination Therapy Left Ventricular Assist Device and a Shared Decision-Making Intervention: The DECIDE-LVAD Trial
Colleen K McIlvennan, Daniel D Matlock, Jocelyn S Thompson, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making
|
May 20, 2020
Decision Aid Implementation among Left Ventricular Assist Device Programs Participating in the DECIDE-LVAD Stepped-Wedge Trial
Daniel D Matlock, Colleen K McIlvennan, Jocelyn S Thompson, et al.
JACC. Heart Failure
|
March 5, 2018
Sudden Death in Heart Failure With Preserved Ejection Fraction: A Competing Risks Analysis From the TOPCAT Trial
Muthiah Vaduganathan, Brian L Claggett, Neal A Chatterjee, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
May 4, 2015
Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
David M Charytan, Eldrin F Lewis, Akshay S Desai, et al.
American Heart Journal
|
October 11, 2011
Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)
John J V McMurray, Hajime Uno, Petr Jarolim, et al.
JACC. Heart Failure
|
October 10, 2024
Race in Heart Failure: A Pooled Participant-Level Analysis of the Global PARADIGM-HF and PARAGON-HF Trials
Henri Lu, Brian L Claggett, Milton Packer, et al.
European Journal of Heart Failure
|
December 18, 2024
Mortality after high-risk myocardial infarction over the last 20 years: Insights from the VALIANT and PARADISE-MI trials
Alberto Foà, Maria A Pabon, Eugene Braunwald, et al.
European Journal of Heart Failure
|
December 26, 2006
Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM
Eldrin F Lewis, Gervasio A Lamas, Eileen O'Meara, et al.
European Journal of Heart Failure
|
July 26, 2024
Acute changes in kidney function and outcomes following an acute myocardial infarction: Insights from PARADISE-MI
Finnian R Mc Causland, Martina M McGrath, Brian L Claggett, et al.
Page
of 22